[Tuberculosis in patients with human immunodeficiency virus infection]. 1997

H Nagai, and A Hebisawa, and S Akagawa, and Y Kawabe, and H Shishido, and A Kurashima, and K Sato, and M Mori, and T Katayama
Department of Pulmonary Diseases, Tokyo National Chest Hospital, Japan.

Six men (mean age: 36.3 +/- 29 years) infected with the human immunodeficiency virus (HIV), four Japanese and two from Myammar, were admitted to our hospital for treatment of tuberculosis. In five, HIV positivity on serologic testing was first found when tuberculosis was diagnosed. The mean CD4 cell count was 37.3 +/- 29.6/microliters. Results of tuberculin skin tests were negative in 5 patients. One patient had pulmonary tuberculosis and 5 had miliary tuberculosis. Hilar and mediastinal lymphadenopathy was found on chest X-ray films in 4 patients and superficial lymphadenopathy was found in all patients. All patients had positive mycobacterial cultures of sputum and 2 patients had positive tests for acid-fast bacilli on smears of lymph-node aspirates. In one patient with tuberculosis meningitis, a culture of cerebrospinal fluid for acid-fast bacilli was positive. Epithelioid cell granulomas were found in samples of lung, liver, and bone marrow from 4 patients. Mycobacterium tuberculosis was isolated from all patients, and was not resistant to isoniazid, rifampicin, ethambutol, or streptomycin. Therefore all patients responded well to treatment of tuberculosis.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D014376 Tuberculosis Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS. Koch's Disease,Kochs Disease,Mycobacterium tuberculosis Infection,Infection, Mycobacterium tuberculosis,Infections, Mycobacterium tuberculosis,Koch Disease,Mycobacterium tuberculosis Infections,Tuberculoses
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D017088 AIDS-Related Opportunistic Infections Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus. HIV-Related Opportunistic Infections,Opportunistic Infections, AIDS-Related,Opportunistic Infections, HIV-Related,AIDS Related Opportunistic Infections,AIDS-Related Opportunistic Infection,HIV Related Opportunistic Infections,HIV-Related Opportunistic Infection,Infection, HIV-Related Opportunistic,Infections, HIV-Related Opportunistic,Opportunistic Infection, AIDS-Related,Opportunistic Infection, HIV-Related,Opportunistic Infections, AIDS Related,Opportunistic Infections, HIV Related

Related Publications

H Nagai, and A Hebisawa, and S Akagawa, and Y Kawabe, and H Shishido, and A Kurashima, and K Sato, and M Mori, and T Katayama
February 1999, The New England journal of medicine,
H Nagai, and A Hebisawa, and S Akagawa, and Y Kawabe, and H Shishido, and A Kurashima, and K Sato, and M Mori, and T Katayama
December 1999, Seminars in respiratory infections,
H Nagai, and A Hebisawa, and S Akagawa, and Y Kawabe, and H Shishido, and A Kurashima, and K Sato, and M Mori, and T Katayama
June 1991, The New England journal of medicine,
H Nagai, and A Hebisawa, and S Akagawa, and Y Kawabe, and H Shishido, and A Kurashima, and K Sato, and M Mori, and T Katayama
July 1990, The Journal of infectious diseases,
H Nagai, and A Hebisawa, and S Akagawa, and Y Kawabe, and H Shishido, and A Kurashima, and K Sato, and M Mori, and T Katayama
November 1990, Chest,
H Nagai, and A Hebisawa, and S Akagawa, and Y Kawabe, and H Shishido, and A Kurashima, and K Sato, and M Mori, and T Katayama
January 1990, Intensive care medicine,
H Nagai, and A Hebisawa, and S Akagawa, and Y Kawabe, and H Shishido, and A Kurashima, and K Sato, and M Mori, and T Katayama
November 1991, Medicine,
H Nagai, and A Hebisawa, and S Akagawa, and Y Kawabe, and H Shishido, and A Kurashima, and K Sato, and M Mori, and T Katayama
February 2000, Indian journal of pediatrics,
H Nagai, and A Hebisawa, and S Akagawa, and Y Kawabe, and H Shishido, and A Kurashima, and K Sato, and M Mori, and T Katayama
April 1996, American journal of respiratory and critical care medicine,
H Nagai, and A Hebisawa, and S Akagawa, and Y Kawabe, and H Shishido, and A Kurashima, and K Sato, and M Mori, and T Katayama
January 1990, Medicina,
Copied contents to your clipboard!